GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Proto Script Pharmaceutical PSCR · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2016

Revenue

—

FY2014FY2016

Net income

−$33,143

FY2014FY2016

Free cash flow

−$38,210

FY2014FY2016

Shareholders' equity

−$77,062

FY2014FY2016

Income statement

Fiscal years

FY2016FY2015FY2014
Revenue—$881,442$947,993
Gross profit—$694,295$689,642
Operating income−$33,143−$146,686−$232,040
Net income−$33,143−$145,249−$239,217
Diluted earnings per share-0.00-0.00-0.01

Balance sheet

At each fiscal year end

FY2016FY2015FY2014
Total assets$11,750$198,941$453,713
Cash and short-term investments—$9,090—
Total liabilities$88,812$136,699$130,196
Debt$81,840$36,159—
Shareholders' equity−$77,062$62,242$323,517
Shares outstanding94m30m30m

Cash flow

Fiscal years

FY2016FY2015FY2014
Cash from operations−$38,210$38,073−$122,214
Capital spending—−$6,064−$2,077
Free cash flow−$38,210$32,009−$124,291
Dividends paid—−$90,229—

Latest quarters

By quarter end

Sept 2017Jun 2017Mar 2017Dec 2016Sept 2016Jun 2016Dec 2015Nov 2015
Revenue$251,974$114,374$138,281$100,349$213,826$131,573——
Gross profit$213,776$30,075$107,341$617$174,430$74,932——
Operating income−$85,455−$244,193−$261,734−$379,570$149−$67,750−$1,828−$10,000
Net income−$283,653−$332,567−$505,868−$7.3m$149−$67,750−$1,828−$10,000
Diluted earnings per share-0.01-0.01-0.01-0.080.00-0.00-0.00—
Total assets$234,557$166,281$229,085$170,191$269,126$244,799$40—
Cash and short-term investments——$56,363$3,507$5,796$16,528$40—
Debt$372,745$237,884$69,143$51,290$82,234$51,724——
Shareholders' equity−$1.4m−$1.2m−$825,604−$319,736−$22,126$83,988−$56,412−$50,000

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return0%50%-9%2650%4398%2397%234%-47%145%1437%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-for-1 split · 13 Oct 2016

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.